Month: December 2025

Regulatory momentum, precision diagnostics, and late-stage CNS execution accelerate across neurology Today’s NeuroPulse reflects a neurology sector translating scientific validation into regulatory action, late-stage execution, and scalable infrastructure. Across Alzheimer’s disease, stroke, autism, ALS, epilepsy, and rare neurodevelopmental conditions, the common thread is clear: platforms enabling earlier diagnosis, biologically targeted intervention, and real-world evidence generation … Read more

Today’s NeuroPulse tracks critical momentum across neurology, neurotechnology, and CNS drug development, with regulatory clearances, late-stage clinical readouts, and platform expansions reshaping near-term treatment and access dynamics. From FDA progress in epilepsy neuromodulation and adaptive sleep apnea devices to Phase 2 and Phase 3 data in Alzheimer’s disease, social anxiety, and pediatric brain cancer, today’s … Read more

The neurology landscape advanced on multiple fronts today, spanning rare pediatric disease regulation, progressive multiple sclerosis setbacks, epilepsy drug financing, augmented-reality–guided neurosurgery, and expanded commercial reach for psychiatric therapies in Asia. Together, these developments reflect a field balancing regulatory scrutiny with accelerating innovation, particularly in rare disorders, surgical precision, and infrastructure that shortens the path … Read more